Acute myeloid leukemia (AML) is the 6th leading cause of cancer-related death in the United States. Although up to 40% of adult patients are responsive to standard chemotherapy, almost all relapse and progress to resistant disease. Most AML patients display no cytogenetic abnormalities or driver mutations, which poses a significant challenge for designing targeted therapy. Combination therapy may also be useful for preventing resistance and improving overall survival. Recent advances in epigenomics have shed light on cellular reprogramming in cancer. Epigenetic proteins can modulate gene expression to induce pathways that increase cell proliferation and decrease differentiation. Coactivator-associated arginine methyltransferase 1 (CARM1) is an epigenetic protein overexpressed in AML. CARM1 has been identified as a key regulator of myeloid differentiation and cancer progression; and is overexpressed in primary, resistant, and recurrent AML. CARM1?s mechanistic role in AML induction and progression (including relevant substrates and regulation) is still unclear, which presents an additional challenge for clinicians to design new therapies. To address gaps in our current understanding of CARM1 function and the need for new AML therapies, I aim to (1) Identify compounds that target CARM1 expression and compounds that work in synergy with a known CARM1 inhibitor in AML and (2) Identify novel chemotypes that directly inhibit CARM1 using a hybrid approach of machine learning and simulations of small molecule-protein interactions.
These aims support key goals of the National Cancer Institute (NCI) and Precision Medicine Initiative, including (1) understanding cancer progression, (2) genomic analysis, (3) advancing precision medicine, (4) bioinformatics and (5) translational research.

Public Health Relevance

Acute myeloid leukemia (AML) is a cancer of the bone marrow, where immature cells accumulate and disrupt the production of normal blood cells, disrupting normal blood formation and organ function. Despite advances in research, AML patients are typically treated with chemotherapy agents that often fail to cure them and frequently lead to relapse. We propose to create new therapies for repressing AML based on targeting the epigenome, or the pattern of chemical modification of DNA and histones, the proteins that package and order DNA to promote gene expression.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Predoctoral Individual National Research Service Award (F31)
Project #
5F31CA228331-03
Application #
10056204
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Ogunbiyi, Peter
Project Start
2018-11-01
Project End
2022-10-31
Budget Start
2020-11-01
Budget End
2021-10-31
Support Year
3
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Miami School of Medicine
Department
Pharmacology
Type
Schools of Medicine
DUNS #
052780918
City
Coral Gables
State
FL
Country
United States
Zip Code
33146